Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
NCT05186974
Active Not Recruiting
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: Alaska Oncology and Hematology, LLC., Anchorage, Alaska +100 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
NCT04854499
Terminated
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in patients with head and neck squamous cell carcinoma (HNSCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: Ironwood Cancer and Research Center, Chandler, Arizona +87 locations
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Phase III Study of AK112 for NSCLC Patients
NCT06396065
Active Not Recruiting
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: CBCC Global Research, Bakersfield, California +73 locations
Conditions: Non-Squamous Non-small Cell Lung Cancer
Register for Updates
Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02470585
Terminated
The primary objective of the study was to evaluate whether progression-free survival (PFS) was prolonged with the addition of veliparib to standard platinum-based chemotherapy (carboplatin/paclitaxel \[C/P\]) and continued as maintenance therapy compared with chemotherapy alone.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/02/2024
Locations: University of Alabama at Birmingham - Main /ID# 138087, Birmingham, Alabama +209 locations
Conditions: Ovarian Cancer, Ovarian Neoplasm
Register for Updates
First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer
NCT03873883
Completed
Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of EOS100850 (Inupadenant) as a Single Agent and in Combination with Pembrolizumab and/or Chemotherapy in Participants with Advanced Cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Karmanos Cancer Institute, Michigan Center, Michigan +18 locations
Conditions: Solid Tumor, Adult
Register for Updates
SGI-110 in Combination With Carboplatin in Ovarian Cancer
NCT01696032
Completed
A 2-part, Phase 2 controlled, open-label, randomized study in participants with platinum-resistant recurrent ovarian cancer. In Part 1, participants received SGI-110 and carboplatin. The optimum dose of SGI-110 (guadecitabine) was identified in Part 1 based on safety and efficacy. In Part 2, participants were randomized to receive the dose identified in Part 1 plus carboplatin or one of four treatment of choice at the discretion of the investigator. The treatment of choice consisted of topotecan... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/31/2024
Locations: Norris Comprehensive Cancer Center- University of Southern California, Los Angeles, California +23 locations
Conditions: Ovarian Cancer
Register for Updates
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
NCT04025879
Active Not Recruiting
The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Local Institution - 0104, Tampa, Florida +107 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Paediatric Hepatic International Tumour Trial
NCT03017326
Active Not Recruiting
The PHITT trial is an over-arching study for patients with Hepatoblastoma (HB) and Hepatocellular Carcinoma (HCC). This trial will use a risk-adapted approach to the treatment of children diagnosed with HB. Children with HCC will be included as a separate cohort.
Gender:
ALL
Ages:
30 years and below
Trial Updated:
05/09/2024
Locations: St. Anna Kinderspital, Vienna, Not set +31 locations
Conditions: Hepatoblastoma, Carcinoma, Hepatocellular
Register for Updates
An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma
NCT02265770
Recruiting
The overall aim of this project is to improve the outcome of patients diagnosed with ependymoma by improving and harmonising the staging and the standard of care of this patient population and to improve the investigators understanding of the underlying biology thereby informing future treatment. The program will evaluate new strategies for diagnosis (centralized reviews of pathology and imaging) and new therapeutic strategies in order to develop treatment recommendations. Patients will be str... Read More
Gender:
ALL
Ages:
22 years and below
Trial Updated:
04/25/2024
Locations: Medical University of Graz-Department of Pediatrics and Adolescent Medicine, Graz, Not set +39 locations
Conditions: Childhood Ependymoma
Register for Updates
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
NCT02899299
Completed
The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Ucsf, San Francisco, California +108 locations
Conditions: Mesothelioma
Register for Updates
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
NCT05080556
Recruiting
ACTOv will compare standard 3-weekly carboplatin (AUC5), to carboplatin delivered according to an AT regimen. The AT regimen will modify carboplatin dose according to changes in the clinical-standard serum biomarker CA125 as a proxy measure of total tumour burden and an individual patient's response to the most recent chemotherapy treatment. AT could prolong sensitivity to carboplatin and extend tumour control, while simultaneously reducing chemotherapy dose and drug-induced toxicity. Carboplati... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: University College London Hospitals, London, Not set
Conditions: Ovarian Cancer, Relapsed Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Endometrioid Carcinoma, High Grade Serous Carcinoma, Ovary Cancer
Register for Updates
Pembrolizumab in Untreated Extensive SCLC
NCT02580994
Completed
This is a multicenter, open-label, two armed, controlled, and randomized phase II trial investigating the activity of pembrolizumab in combination with standard chemotherapy in Extensive Disease (ED)-SCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/08/2023
Locations: Centre Hospitalier d'Avignon - Hopital Duffaut, Avignon, Not set +17 locations
Conditions: Small Cell Lung Cancer (SCLC)
Register for Updates